Recrutamento encerrado
FASE
Número Europeu  2021-000602-17
CABL001A2001B ASC4MORE RollOver
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Detalhes
Destaques